A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated nonsmall-cell lung cancer

导出原文传递

翻译打印收藏纠错

作者： Spira,A.I. ^[1] ; Iannotti,N.O. ^[2] ; Savin,M.A. ^[3] ; Neubauer,M. ^[4] ; Gabrail,N.Y. ^[5] ; Yanagihara,R.H. ^[6] ; Zang,E.A. ^[7] ; Cole,P.E. ; Shuster,D. ; Das,A.

作者单位： Kansas City Cancer Center, Kansas City, MO, United States ^[1] Gabrail Cancer Center, Canton, OH, United States ^[2] St Louise Hospital, Gilroy, CA, United States ^[3] Eisai Inc., Woodcliff Lake, NJ, United States ^[4] Virginia Cancer Specialists, INOVA Thoracic Oncology Program, 8503 Arlington Blvd, Fairfax, VA ^[5] Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, FL, United States ^[6] Texas Oncology, Texas Cancer Center at Medical City, Dallas, TX, United States ^[7]

关键词 Chemotherapy Halichondrin B Microtubule Monotherapy Tubulin

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交